Revenue and Growth - Total revenue for the three months ended September 30, 2025, was $1,757,094, an increase of 22.6% compared to $1,433,151 for the same period in 2024[14] - Clinic revenue for the nine months ended September 30, 2025, reached $5,175,870, up from $4,763,131 in 2024, reflecting an increase of 8.7%[14] - For the nine months ended September 30, 2025, total consolidated revenue was $5,257,933, an increase from $4,846,034 for the same period in 2024, representing an increase of approximately 8.5%[189][190] - The Clinic Services segment generated revenue of $5,175,870, while the INVOcell Device segment contributed $82,063, with no revenue from the Therapeutics segment[189] Expenses and Losses - Total operating expenses for the three months ended September 30, 2025, were $3,392,578, compared to $2,733,553 in 2024, representing a 24.2% increase[14] - The net loss from continuing operations for the three months ended September 30, 2025, was $2,644,625, compared to a loss of $1,630,662 in 2024, indicating a deterioration in performance[14] - The net loss for the nine months ended September 30, 2025, was $25,333,069, compared to a net loss of $5,472,345 for the same period in 2024[22] - The Company reported a loss before taxes of $25,333,069 for the nine months ended September 30, 2025, compared to a loss of $5,441,250 for the same period in 2024[189][190] Cash and Assets - Cash and cash equivalents as of September 30, 2025, were $355,891, down from $619,520 as of December 31, 2024, a decrease of 42.5%[12] - Total assets decreased to $18,832,198 as of September 30, 2025, from $46,449,182 as of December 31, 2024, a decline of 59.5%[12] - As of September 30, 2025, the Company had total assets of $7,831,342 in the Fertility Clinic segment and $34,671 in the INVOcell segment[189] Liabilities and Equity - Total liabilities as of September 30, 2025, were $12,983,476, down from $26,244,709 as of December 31, 2024, a reduction of 50.6%[12] - As of March 31, 2025, total stockholders' equity is $3,335,365, with accumulated deficit of $(84,873,449)[18] - The Company has substantial doubt about its ability to continue as a going concern for at least one year from the date the financial statements are issued[62] Impairment and Losses - The company reported an impairment loss of $1,397,353 for the nine months ended September 30, 2025[14] - The company reported an impairment loss of $16,042,422 during the nine months ended September 30, 2025[22] - The Company recognized a gain on settlement of $714,500 related to the Settlement Agreement with Dr. Pritts, alongside an impairment loss of $1,397,353[201] Operational Developments - The company has two operational INVO Centers and one IVF clinic in the United States, focusing on expanding access to assisted reproductive technology[25] - The company divested 80.1% of NAYA Therapeutics, Inc. in the second quarter of 2025 to concentrate exclusively on the fertility marketplace[25] - The Company plans to grow the Wisconsin Fertility Institute and pursue the acquisition of additional U.S.-based, profitable IVF clinics over the next 12 months[61] Financing and Stock Activity - The Company raised $2.2 million from the sale of preferred stock, $1.0 million from the exercise of warrants, and $8.7 million in net proceeds from a public offering during the first nine months of 2025[61] - The Company raised net proceeds of $8,747,880 from the January 2025 Offering, which included 378,199 units at an offering price of $25.20 per unit[164] - A reverse stock split at a ratio of 1-for-12 was approved on February 24, 2025, and took effect on March 18, 2025, reducing authorized common stock to 12,500,000 shares[136] Future Outlook - The company anticipates future growth through the introduction of new products and market expansion strategies[10] - Management highlighted the importance of regulatory approvals and market acceptance for future product candidates[10] - The company intends to seek additional innovative fertility-focused technologies to license or acquire for its operating clinics[25]

Revenue and Growth - Total revenue for the three months ended September 30, 2025, was $1,757,094, an increase of 22.6% compared to $1,433,151 for the same period in 2024[14] - Clinic revenue for the nine months ended September 30, 2025, reached $5,175,870, up from $4,763,131 in 2024, reflecting an increase of 8.7%[14] - For the nine months ended September 30, 2025, total consolidated revenue was $5,257,933, an increase from $4,846,034 for the same period in 2024, representing an increase of approximately 8.5%[189][190] - The Clinic Services segment generated revenue of $5,175,870, while the INVOcell Device segment contributed $82,063, with no revenue from the Therapeutics segment[189] Expenses and Losses - Total operating expenses for the three months ended September 30, 2025, were $3,392,578, compared to $2,733,553 in 2024, representing a 24.2% increase[14] - The net loss from continuing operations for the three months ended September 30, 2025, was $2,644,625, compared to a loss of $1,630,662 in 2024, indicating a deterioration in performance[14] - The company reported a loss from operations of $1,635,484 for the three months ended September 30, 2025, compared to a loss of $1,300,402 in 2024, reflecting increased operational challenges[14] - The net loss for the nine months ended September 30, 2025, was $25,333,069, compared to a net loss of $5,472,345 for the same period in 2024[22] - The Company reported a net loss before taxes of $25,333,069 for the nine months ended September 30, 2025, compared to a loss of $5,441,250 for the same period in 2024[189][190] Cash and Assets - Cash and cash equivalents as of September 30, 2025, were $355,891, down from $619,520 as of December 31, 2024, a decrease of 42.5%[12] - Total assets decreased to $18,832,198 as of September 30, 2025, from $46,449,182 as of December 31, 2024, a decline of 59.5%[12] - The carrying value of the Company's investment in unconsolidated VIEs was $613,771 as of September 30, 2025, down from $740,759 in December 2024[79] - Cash used in operating activities for the nine months ended September 30, 2025, was $7,039,692, significantly higher than $2,357,021 in 2024[22] Equity and Stock Issuance - As of March 31, 2025, the total stockholders' equity for INVO Fertility, Inc. was $3,335,365, with accumulated deficit amounting to $(84,873,449)[18] - Common stock issued to service providers totaled 10,167 shares, raising $692,265 in capital[18] - A total of 87,720 shares were issued for debt conversion, resulting in $2,680,000 in additional capital[18] - The Company completed a public offering on January 14, 2025, raising net proceeds of $8,747,880 from the sale of 378,199 units at an offering price of $25.20 per unit[164] Strategic Focus and Future Plans - The company anticipates continued focus on market expansion and new product development in the upcoming quarters[10] - The company intends to seek additional innovative fertility-focused technologies to license or acquire for its operating clinics[25] - The Company plans to grow the Wisconsin Fertility Institute and pursue the acquisition of additional U.S.-based, profitable IVF clinics over the next 12 months[61] Regulatory and Market Considerations - Management highlighted the importance of regulatory approvals and market acceptance for future product candidates as key factors influencing performance[10] - The Company is in the process of assessing the impacts from the tax law changes in the One Big Beautiful Bill Act but does not expect a material impact on its financial statements[193] Debt and Financing - The Company incurred $60,667 in interest related to demand notes for the nine months ended September 30, 2025[99] - The Company secured a Revenue Loan of $1,500,000 on September 29, 2023, with a maturity date of June 29, 2028, and incurred $288,442 in interest for the nine months ended September 30, 2025[103][104] - The Company incurred accrued compensation of $342,957 as of September 30, 2025, primarily related to paid time off[135] Divestitures and Mergers - The company divested 80.1% of NAYA Therapeutics, Inc. in the second quarter of 2025 to concentrate on the fertility marketplace[25] - The Company divested 80.1% of its subsidiary NTI during the second quarter of 2025, impacting the Therapeutics segment's financial results[188] Impairments and Losses - The company reported an impairment loss of $16,042,422 during the nine months ended September 30, 2025[22] - The Company recognized an impairment of $1,397,353 on the noncompetition agreement related to the WFI acquisition[85]

Vehicle Deliveries and Sales - Total vehicle deliveries reached 140,195 units in Q3 2025, a 12.5% year-over-year increase and a 7.1% quarter-over-quarter increase[3] - Vehicle sales amounted to RMB26,527 million (US$3,726 million) in Q3 2025, reflecting a 7.3% increase from Q3 2024 and a 15.8% increase from Q2 2025[7] - The Zeekr brand delivered 21,423 vehicles in October 2025, contributing to a total of 61,636 vehicles delivered across both brands, a 20.5% increase from the previous month[12] Financial Performance - Total revenues were RMB31,562 million (US$4,434 million) for Q3 2025, representing a 9.1% increase year-over-year and a 15.1% increase quarter-over-quarter[9] - Gross profit for Q3 2025 was RMB6,046 million (US$850 million), a 37.1% increase from Q3 2024 and a 6.9% increase from Q2 2025[9] - Net loss decreased to RMB307 million (US$43 million) in Q3 2025, down 84.9% from Q3 2024[8] - Non-GAAP net loss attributable to ordinary shareholders for Q3 2025 was RMB761 million (US$107 million), a decrease of 63.2% from RMB2,068 million in Q3 2024 and an increase of 109.1% from RMB364 million in Q2 2025[25] - Basic and diluted net loss per share attributed to ordinary shareholders for Q3 2025 was RMB0.31 (US$0.04), compared to RMB0.83 in Q3 2024 and RMB0.15 in Q2 2025[25] - The company reported a comprehensive loss attributable to shareholders of RMB812 million (US$114 million) for Q3 2025[37] Profitability Metrics - Vehicle margin was 15.6% in Q3 2025, compared to 12.6% in Q3 2024, indicating improved profitability[9] Research and Development - Research and development expenses were RMB2,743 million (US$385 million) in Q3 2025, a decrease of 8.6% from Q3 2024[19] - Research and development expenses for Q3 2025 were RMB2,743 million (US$385 million), compared to RMB3,000 million in Q3 2024[34] Assets and Liabilities - Total current assets as of September 30, 2025, were RMB40,592 million (US$5,702 million), down from RMB50,863 million as of December 31, 2024[31] - Total liabilities as of September 30, 2025, were RMB82,651 million (US$11,611 million), compared to RMB82,407 million as of December 31, 2024[32] Cash Position - Cash and cash equivalents totaled RMB8,763 million (US$1,231 million) as of September 30, 2025[20] Strategic Goals - The company aims to enhance its user ecosystem and develop its own software systems and electric vehicle supply chain[21] Share Metrics - Non-GAAP net loss attributable to ordinary shareholders per ADS for Q3 2025 was RMB2.96 (US$0.42), compared to RMB8.10 in Q3 2024[25] - The weighted average number of ordinary shares used in calculating Non-GAAP net loss per share for Q3 2025 was 2,572,968,401[38]

Financial Performance - Fiscal 2025 consolidated revenue was $18.5 billion, a 6% increase year-over-year, with organic revenue growth of 7%[8] - Annualized gross new business reached $1.6 billion, over 12% higher than fiscal 2024, with a client retention rate of 96.3%[21] - Operating income increased 12% year-over-year to $792 million, while adjusted operating income (AOI) grew 12% to $981 million[10] - Fourth quarter revenue was $5.0 billion, a 14% increase year-over-year, with organic revenue growth also at 14%[12] - GAAP EPS for fiscal 2025 was $1.22, compared to $0.99 in fiscal 2024, while adjusted EPS increased 19% to $1.82[11] - Net cash from operations rose 27% to $921 million, and free cash flow grew 41% to $454 million in fiscal 2025[17] - Revenue for the fiscal year ended October 3, 2025, increased to $18,506.3 million, up 6.4% from $17,400.7 million in the previous year[53] - Operating income for the fiscal year was $791.8 million, representing a growth of 12.1% compared to $706.5 million in the prior year[53] - Net income attributable to Aramark stockholders rose to $326.4 million, a 24.3% increase from $262.5 million year-over-year[53] - Basic earnings per share increased to $1.24, up from $1.00, reflecting a 24% growth[53] - For the three months ended October 3, 2025, revenue was $5,048.5 million, a 14.3% increase from $4,416.9 million in the same period last year[55] - Operating income for the three-month period was $217.8 million, slightly down from $218.8 million year-over-year[55] - Cash flows from operating activities for the fiscal year were $921.0 million, compared to $726.5 million in the previous year, indicating a 26.7% increase[59] - Total current assets increased to $3,522.9 million from $3,406.6 million, reflecting a growth of 3.4%[57] - Total liabilities decreased to $10,156.6 million from $10,270.0 million, a reduction of 1.1%[57] - Adjusted operating income margin for the fiscal year was 5.3%, compared to 5.1% in the previous year, indicating improved operational efficiency[61] - Total revenue for the three months ended October 3, 2025, was $5,048,464, representing a 14.3% increase compared to the same period last year[63] - Adjusted operating income for the same period was $288,552, with an adjusted operating income margin of 5.7%[63] - Adjusted net income attributable to Aramark stockholders for the three months ended October 3, 2025, was $151,715, reflecting a 5.6% growth compared to the previous year[65] - Free cash flow for the three months ended October 3, 2025, was $1,051,703, significantly higher than the $889,047 reported in the same period last year[75] - Revenue growth for FSS United States was 13.6%, while FSS International saw a growth of 16.1%[63] - Adjusted earnings per share for the three months ended October 3, 2025, was $0.57, compared to $0.54 in the same period last year, marking a 5.6% increase[65] - Operating income for the three months ended October 3, 2025, was $217,820, with a reported operating income margin of 4.3%[63] - The company reported an adjusted operating income growth of 6.3% for the three months ended October 3, 2025[63] Future Outlook - The company's leverage ratio improved to 3.25x, the lowest level in nearly 20 years[18] - Aramark repurchased over 4 million shares and raised its quarterly dividend by 14% to $0.12 per share[20] - The company anticipates achieving net new business of at least 4% to 5% of prior year revenue in fiscal 2026[22] - Significant new business opportunities are expected to drive profitability through enhanced supply chain capabilities and disciplined cost management[23] - Aramark anticipates fiscal 2026 revenue between $19,550 million and $19,950 million, representing a year-over-year organic growth of +7% to +9%[25] - Adjusted Operating Income for fiscal 2026 is projected to be between $1,100 million and $1,150 million, reflecting a year-over-year increase of +12% to +17%[25] - Adjusted EPS is expected to range from $2.18 to $2.28, indicating a year-over-year growth of +20% to +25%[25] - The company aims to reduce its leverage ratio to under 3x by fiscal 2026, down from 3.25x[25] - Fiscal 2026 revenue guidance includes approximately $100 million of expected favorability from foreign currency translation[25] - Aramark is focused on driving performance by leveraging enterprise-wide capabilities and starting operations for a record number of new clients[25] - The company is maintaining retention momentum and optimizing Global Supply Chain strategies to pursue significant growth opportunities[25] Corporate Responsibility - Aramark has been recognized for its commitment to diversity and social responsibility, appearing on several prestigious lists[27] Financial Metrics - The company uses various financial metrics, including Adjusted Revenue (Organic) and Free Cash Flow, to evaluate performance and profitability[40] Currency Impact - The effect of currency translation negatively impacted revenue by $21,674 for the three months ended October 3, 2025[63] Special Considerations - Estimated impact of the 53rd week on revenue was a reduction of $326,691[77] - Adjusted organic revenue for the fiscal year was $18,179,608[77]

Mergers and Acquisitions - ConnectM completed a merger with Monterey Capital Acquisition Corporation, resulting in the issuance of 14,500,000 shares of common stock and becoming a publicly listed company[199]. - ConnectM's acquisition of Cambridge Energy Resources Pvt. Ltd. for approximately $1,135,000 is expected to increase India-based operations from 5% to 15% of global revenue, approximately $10,000,000 annualized, over the next twelve months[210]. - The acquisition of Amperics Holdings LLC's assets on November 3, 2025, involved 2,700,000 shares of common stock, with no cash consideration paid[229][230]. - The company acquired approximately 76 acres of land in India through the acquisition of Geo Impex LLC, which is expected to support the development of a multimodal logistics park and an AI-enabled data center campus[239]. Financial Performance - Revenues increased by $2,709,000 or 45% to approximately $8,707,000 for the three months ended September 30, 2025, driven by the new Logistics segment and geographic market expansion[258]. - For the nine months ended September 30, 2025, revenues increased by $9,826,000 or 60% to approximately $26,207,000, primarily due to the Logistics segment and service network expansion[259]. - Cost of revenues for the three months ended September 30, 2025, increased by $1,632,000 or 39% to approximately $5,832,000, largely due to the new Logistics segment[260]. - For the nine months ended September 30, 2025, cost of revenues rose by $6,336,000 or 58% to approximately $17,346,000, driven by the Logistics segment[261]. - Total other income for the three months ended September 30, 2025, was $1,823,683, a significant increase of $9,154,489 compared to the previous year[264]. Cash Flow and Financing - Net cash used in operating activities for the nine months ended September 30, 2025, was approximately $6,697,000, primarily due to a net loss of approximately $11,376,000[271]. - Net cash provided by financing activities for the nine months ended September 30, 2025, was approximately $6,481,000, primarily from proceeds of convertible debt[276]. - The Company entered into twelve convertible note agreements in Q1 2025, raising $2,530,000 with interest rates of 20.0% per annum[207]. - A total of 15,290,930 shares were issued in exchange for $4,435,000 in secured promissory notes and convertible notes during April and May 2025[214]. - ConnectM issued 3,658,333 shares for gross proceeds of approximately $805,000 during May and June 2025[218]. Expenses and Liabilities - Selling, general and administrative expenses decreased by $1,361,000 or 31% to approximately $5,691,000 for the three months ended September 30, 2025[262]. - For the nine months ended September 30, 2025, selling, general and administrative expenses increased by $7,908,000 or 76% to approximately $18,271,000, influenced by public company costs and marketing expenses[263]. - The company extinguished certain liabilities, recognizing a gain of approximately $2,391,000 for the three months ended September 30, 2025[265]. - The Company reported a settlement agreement with Last Horizon, issuing 13,744,131 shares to resolve $8,908,000 in overdue liabilities[203]. Strategic Initiatives - The company formed Keen Labs Operations LLC on October 27, 2025, to consolidate and expand its AI and technology operations, focusing on product development and growth in energy transition, logistics, and mobility sectors[227]. - The company entered into a distribution agreement with Greentech Renewables on November 10, 2025, to expand the distribution of its high-efficiency heat pumps, expected to contribute to future sales growth starting in 2026[242][244]. - The company is evaluating the integration of acquired technology into Keen Labs and assessing potential segment reporting changes following the acquisitions[234][240]. - The company plans to finalize purchase accounting for the acquisitions within the measurement period, including the identification of identifiable intangible assets and goodwill[234][241]. Compliance and Regulations - The company anticipates increased selling, general, and administrative expenses due to scaling headcount and compliance with public company regulations[254][255]. - As of September 30, 2025, the company was required to maintain a minimum cash balance of approximately $2,499,000 under the SEPA Convertible Note[245]. - The accounting principles used in preparing the condensed consolidated financial statements conform to U.S. GAAP[283]. - The fair value of the 3(a)(10) Settlement Agreement is re-measured each reporting period, with significant assumptions impacting the concluded fair value[285]. Future Outlook - The company expects to derive future revenue from high-margin recurring products, expanded service offerings, and international expansion efforts[248]. - Future contractual obligations and commitments are based on the terms of relevant agreements and may differ from actual payments due to future events[279]. - The company incurs contractual obligations in the normal course of operations, including future cash payments under existing contracts such as debt and lease agreements[280].

Mergers and Acquisitions - ConnectM completed a merger with Monterey Capital Acquisition Corporation, resulting in the issuance of 14,500,000 shares of common stock and becoming a publicly listed company[199]. - ConnectM's acquisition of Cambridge Energy Resources Pvt. Ltd. for approximately $1,135,000 is expected to increase India-based operations from 5% to 15% of global revenue, approximately $10,000,000 annualized, over the next twelve months[210]. - The acquisition of Amperics' nanotechnology-based energy-storage business was completed on November 3, 2025, with consideration consisting of 2,700,000 shares of common stock[229][230]. - The company acquired approximately 86.22% of the voting equity interests of Geo Impex India through an Exchange and Acquisition Agreement, issuing 33,300,000 shares and a promissory note of $788,900[235][236][237]. - The principal asset acquired from Geo Impex India includes approximately 76 acres of land for developing a multimodal logistics park and an AI-enabled data-center campus[239]. Financial Performance - Revenues increased by $2,709,000 or 45% to approximately $8,707,000 for the three months ended September 30, 2025, driven by the new Logistics segment and geographic market expansion[258]. - For the nine months ended September 30, 2025, revenues increased by $9,826,000 or 60% to approximately $26,207,000, primarily due to the Logistics segment and service network expansion[259]. - Cost of revenues rose by $1,632,000 or 39% to approximately $5,832,000 for the three months ended September 30, 2025, largely due to the new Logistics segment[260]. - For the nine months ended September 30, 2025, cost of revenues increased by $6,336,000 or 58% to approximately $17,346,000, driven by the Logistics segment[261]. - Total other income for the three months ended September 30, 2025 was $1,823,683, a significant increase of $9,154,489 compared to a loss of $7,330,806 in the same period of 2024[264]. - For the nine months ended September 30, 2025, total other expense was $(1,967,038), a decrease of $7,320,394 from $(9,287,432) in the same period of 2024[265]. Expenses and Cash Flow - Selling, general and administrative expenses decreased by $1,361,000 or 31% to approximately $5,691,000 for the three months ended September 30, 2025[262]. - For the nine months ended September 30, 2025, selling, general and administrative expenses increased by $7,908,000 or 76% to approximately $18,271,000, influenced by public company costs and marketing expenses[263]. - Net cash used in operating activities for the nine months ended September 30, 2025 was approximately $(6,697,000), primarily due to a net loss of approximately $(11,376,000)[271]. - As of September 30, 2025, the minimum cash balance requirement was approximately $2,499,000[269]. - Net cash used in operating activities for the nine months ended September 30, 2024 was approximately $2,772,000, primarily due to a net loss of approximately $14,685,000, offset by approximately $8,694,000 of noncash items[273]. Financing Activities - The Company entered into twelve convertible note agreements in Q1 2025, raising $2,530,000 with interest rates of 20.0% per annum[207]. - The Company issued 3,658,333 shares for gross proceeds of approximately $805,000 during May and June 2025[218]. - ConnectM's Q2 2025 Convertible Notes raised $1,026,000, with interest rates of 20.0% per annum and various conversion terms[219]. - On October 23, 2025, the company issued a convertible promissory note of $275,000 with a 10% original issue discount, resulting in net proceeds of $250,000[226]. - The company formed Keen Labs Operations LLC on October 27, 2025, to consolidate and expand its AI and technology operations, focusing on product development and growth in energy transition, logistics, and mobility sectors[227]. Agreements and Obligations - The Company reported a settlement agreement with Last Horizon, issuing 13,744,131 shares to resolve $8,908,000 in overdue liabilities[203]. - ConnectM entered into a structured repayment plan for a remaining debt balance of approximately $3.1 million with Libertas Funding, LLC, including a right to redeem shares post-repayment[223]. - A distribution agreement was signed with Greentech Renewables on November 10, 2025, to expand the distribution of Keen-branded high-efficiency heat pumps, expected to contribute to future sales growth starting in 2026[242][244]. - The company anticipates increased selling, general, and administrative expenses due to scaling headcount and compliance with public company regulations[254][255]. - Future contractual obligations and commitments are based on the terms of relevant agreements and may differ from actual payments due to future events[279]. Accounting and Compliance - The company is evaluating the accounting implications of its agreements under ASC 606, including revenue recognition and variable considerations[244]. - The fair value of the 3(a)(10) Settlement Agreement is re-measured each reporting period, with significant assumptions impacting the concluded fair value[285]. - The company did not have any off-balance sheet arrangements during the periods presented[278]. - The company incurs contractual obligations in the normal course of operations, including future cash payments under existing contracts such as debt and lease agreements[280].

Exhibit 99.1 This Management's Discussion and Analysis ("MD&A") comments on the financial performance and financial condition of PowerBank Corporation ("PowerBank" or the "Company") for the three months ended September 30, 2025. This MD&A is presented as of November 14, 2025 and was reviewed and approved by our Board of Directors (the "Board"). Unless otherwise stated or the context otherwise indicates, all references to "PowerBank", the "Company", "we", "us" or "our" refer to PowerBank Corporation together ...

Exhibit 99.1 XPENG Reports Third Quarter 2025 Unaudited Financial Results GUANGZHOU, China, November 17, 2025 — XPeng Inc. ("XPENG" or the "Company," NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle ("Smart EV") company, today announced its unaudited financial results for the three months ended September 30, 2025. Operational and Financial Highlights for the Three Months Ended September 30, 2025 | | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 | 2024Q2 | | --- | --- | --- | --- | --- | --- ...

Financial Performance - Sales for the third quarter of 2025 were NIS 152.8 million (US$ 46.2 million), remaining at the same level compared to the third quarter of 2024[7] - Gross profit increased by 2.6% year-over-year to NIS 43.1 million (US$ 13.0 million), representing 28.2% of revenues[9] - Operating profit increased by 4.1% year-over-year to NIS 18.3 million (US$ 5.5 million)[11] - Net profit for the third quarter was NIS 19.2 million (US$ 5.8 million), or NIS 1.4 (US$ 0.4) per share[13] - Sales for the nine-month period ending September 30, 2025, increased by 5.2% to NIS 458.2 million (US$ 138.6 million)[15] - Gross profit for the first nine months of 2025 increased by 7.5% to NIS 131.7 million (US$ 39.8 million), or 28.7% of revenues[16] - Operating profit before other expenses for the first nine months of 2025 increased by 16.7% to NIS 58.8 million (US$ 17.8 million)[19] - Net profit increased by 52.9% year-over-year to NIS 70.6 million (US$ 21.3 million), or 15.4% of sales[22] Cash and Assets - Cash and securities balance was NIS 225.4 million (US$ 68.2 million) as of September 30, 2025[13] - Total current assets as of September 30, 2025, were NIS 512,859 thousand, slightly down from NIS 516,470 thousand as of September 30, 2024[30] - Total non-current assets increased to NIS 190,289 thousand as of September 30, 2025, from NIS 146,794 thousand in 2024, reflecting a growth of approximately 29.6%[30] - Total current liabilities decreased to NIS 51,941 thousand as of September 30, 2025, from NIS 63,276 thousand in 2024, a reduction of about 18%[30] - Shareholders' equity attributable to owners of the Company increased to NIS 634,616 thousand as of September 30, 2025, compared to NIS 588,794 thousand in 2024, indicating a growth of approximately 7.8%[30] Cash Flow and Receivables - Net cash from continuing operating activities for the nine months ended September 30, 2025, was NIS 38,789 thousand, significantly higher than NIS 16,122 thousand in the same period of 2024[34] - Net cash flows from operating activities for the nine months ended September 30, 2025, were negative at NIS 31,767 thousand, compared to negative NIS 30,029 thousand for the same period in 2024[35] - Cash generated from operations for the three months ended September 30, 2025, was NIS 24,279 thousand, a significant increase from NIS 14,933 thousand in the previous year[35] - The company reported an increase in trade receivables of NIS 17,135 thousand for the nine months ended September 30, 2025, compared to a decrease of NIS 1,764 thousand in the same period of 2024[35] Expenses and Tax - Depreciation and amortization expenses for the nine months ended September 30, 2025, were NIS 5,829 thousand, up from NIS 5,583 thousand in 2024[35] - Income tax paid for the nine months ended September 30, 2025, was NIS 16,757 thousand, compared to NIS 11,171 thousand in 2024[35] Inventory and Marketable Securities - The company experienced a decrease in inventories of NIS 10,177 thousand for the nine months ended September 30, 2025, compared to a decrease of NIS 35,321 thousand in the same period of 2024[35] - The unrealized gains on marketable securities increased to NIS 24,646 thousand for the nine months ended September 30, 2025, compared to NIS 13,058 thousand in 2024[35] Stock-Based Compensation and Exchange Loss - Stock-based compensation reserve increased to NIS 1,039 thousand for the nine months ended September 30, 2025, from NIS 392 thousand in 2024[35] - Exchange loss on cash and cash equivalents was NIS 1,225 thousand for the nine months ended September 30, 2025, compared to a gain of NIS 1,629 thousand in 2024[35] Capital Gains - The company reported a capital gain on the disposal of property, plant, and equipment of NIS 95 thousand for the nine months ended September 30, 2025, down from NIS 143 thousand in 2024[35] Future Developments - The new refrigerated logistics center is expected to open toward the end of the first quarter of 2026, enhancing logistical capabilities and product availability[6]

Financial Performance - Total vehicle deliveries reached 116,007 in Q3 2025, a 149.3% increase from 46,533 in Q3 2024[2] - Quarterly total revenues were RMB20.38 billion (US$2.86 billion), representing a 101.8% year-over-year increase[7] - Gross margin for Q3 2025 was 20.1%, up 4.8 percentage points from 15.3% in Q3 2024[4] - Vehicle margin was 13.1% for Q3 2025, an increase of 4.5 percentage points from 8.6% in Q3 2024[12] - Net loss for Q3 2025 was RMB0.38 billion (US$0.05 billion), a significant reduction of 78.9% from RMB1.81 billion in Q3 2024[20] - Non-GAAP net loss was RMB0.15 billion (US$0.02 billion) for Q3 2025, down 90.1% from RMB1.53 billion in Q3 2024[21] - Revenues from vehicle sales were RMB18.05 billion (US$2.54 billion) for Q3 2025, a 105.3% increase from RMB8.80 billion in Q3 2024[8] - The Company reported total revenues of RMB20.4 billion (approximately US$2.9 billion) for Q3 2025, up from RMB18.3 billion in Q2 2025[40] - Vehicle sales for Q3 2025 reached RMB18.1 billion (approximately US$2.5 billion), compared to RMB16.9 billion in Q2 2025[40] - Gross profit for Q3 2025 was RMB4.1 billion (approximately US$576.5 million), reflecting an increase from RMB3.2 billion in Q2 2025[40] Operational Metrics - Cash and cash equivalents totaled RMB48.33 billion (US$6.79 billion) as of September 30, 2025, compared to RMB35.75 billion a year earlier[25] - Cash and cash equivalents as of September 30, 2025, were RMB17.5 billion (approximately US$2.5 billion)[35] - The Company incurred a loss from operations of RMB751 million (approximately US$105.5 million) in Q3 2025, an improvement from a loss of RMB934.6 million in Q2 2025[40] - XPENG's physical sales network expanded to 690 stores across 242 cities as of September 30, 2025[2] Future Projections - For Q4 2025, the Company expects vehicle deliveries between 125,000 and 132,000, a year-over-year increase of approximately 36.6% to 44.3%[26] - Total revenues are projected to be between RMB21.5 billion and RMB23.0 billion, representing a year-over-year increase of approximately 33.5% to 42.8%[26] Research and Development - Research and development expenses increased by 48.7% year-over-year to RMB2.43 billion (US$0.34 billion) in Q3 2025[14] - The Company is focused on developing in-house advanced driver-assistance systems and intelligent operating systems for its Smart EVs[30] Losses and Challenges - XPeng Inc. reported a net loss of RMB 1,807,720,000 for the three months ended September 30, 2025, compared to a net loss of RMB 477,754,000 in the previous quarter, representing a significant increase in losses[41] - The company's total comprehensive loss attributable to ordinary shareholders was RMB 2,092,063,000 for the same period, up from RMB 494,168,000 in the previous quarter[43] - Loss from operations was RMB 1,847,096,000, compared to RMB 934,649,000 in the previous quarter, indicating a worsening operational performance[44] - Non-GAAP net loss attributable to ordinary shareholders was RMB 1,531,572,000, compared to RMB 385,283,000 in the previous quarter, reflecting increased operational challenges[45] Shareholder Information - The weighted average number of ordinary shares used in computing net loss per ordinary share was approximately 1,893,857,778 for the quarter[43] - Basic and diluted net loss per ordinary share attributable to ordinary shareholders was RMB (0.95), compared to RMB (0.25) in the previous quarter[43] Other Financial Metrics - The company experienced a fair value loss on derivative liability relating to contingent consideration of RMB 162,185,000 during the quarter[44] - Share-based compensation expenses amounted to RMB 113,963,000, slightly down from RMB 126,475,000 in the previous quarter[44] - XPeng Inc. reported an investment loss on long-term investments of RMB (216,768,000) for the quarter, a significant decline from a gain of RMB 24,401,000 in the previous quarter[41] - The company recorded an exchange gain from foreign currency transactions of RMB 47,565,000, down from RMB 142,684,000 in the previous quarter[41]